ADCT’s Q4 Cash, ZYNLONTA Catalysts, and a Royalty Backstop: What the 2025 Results Portend for ADCs

Ticker: ADCT. In the language of earnings, the message touches on EPS and revenue forecast dynamics, even if the company does not yet present traditional EPS figures. This piece digs into how ADC Therapeutics SA’s 2025 results shape the near-term path for the stock, the ZYNLONTA program, and the broader antibody-drug conjugate (ADC) sector.

Executive snapshot

ADC Therapeutics SA (ADCT) reported fourth-quarter and full-year 2025 results alongside operational updates. The key takeaways are a modest improvement in net product revenue, a disciplined spend profile as the company winds down discontinued programs, and a heavy emphasis on upcoming LOTIS trials that could redefine the commercial value of ZYNLONTA in 2L+ DLBCL and related indications. The company’s current cash and equivalents of about $261.3 million as of December 31, 2025 provide a runway at least into 2028, a comforting line for a development-stage business navigating multi-tranche trial data and potential regulatory milestones.

Financial highlights at a glance

Net product revenue for Q4 2025: approximately $22.3 million; full-year 2025 revenue around $73.6 million. These figures sit in the context of prior-year levels and reflect the variability in ordering patterns even as underlying demand remains broadly stable.
R&D expense for Q4 2025: about $18.2 million; full-year 2025 R&D roughly $104.0 million. The year-over-year decline in quarterly R&D is tied to winding down discontinued programs and IND-enabling work on non-core assets, offset by ongoing ZYNLONTA trials and IND-enabling activity for a PSMA-targeting ADC.
S&M expense around $12.0 million in Q4 2025, with the full-year figure around $43.4 million.
Cash position and equivalents stood at $261.3 million as of December 31, 2025, supporting an expected cash runway into 2028.
Strategic financing activity includes an amendment to HealthCare Royalty financing, providing enhanced strategic flexibility amid ongoing programmatic milestones.

Operational updates and near-term catalysts

The company continues to push LOTIS-5, its Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab for 2L+ DLBCL. Topline results are anticipated in 2Q 2026, with full LOTIS-5 data and LOTIS-7 data in 2L+ DLBCL anticipated by year-end 2026. If data are favorable, the plan includes a supplemental Biologics License Application (sBLA) submission to the FDA, potential compendia inclusions in 2027, and a confirmatory- or regulatory-approval pathway for LOTIS-5 in mid- to late-2027. The scale of the opportunity hinges on durable response rates and safety signals in the combination regimen.

LOTIS-7 remains in ongoing development, with data anticipated by year-end 2026. December 2025 updates from LOTIS-7 suggested strong early efficacy signals in combination with the bispecific antibody glofitamab (COLUMVI) in r/r DLBCL, setting a potentially meaningful data tailwind for ZYNLONTA in combination regimens.

Beyond LOTIS, the company notes ongoing investigator-initiated trials (IITs) evaluating ZYNLONTA in additional B-cell malignancies. Publication timelines target end of 2026 to mid-2027 for UM Sylvester-led trials in follicular lymphoma (r/r FL) and marginal zone lymphoma (MZL), with potential regulatory and compendia pathways contingent on positive data.

Financing structure and strategic flexibility

A notable element of the company’s 2025 narrative is the amendment to the HealthCare Royalty financing agreement. This instrument, effectively a financing backstop tied to future product sales, offers cash-flow flexibility that can support ongoing clinical development and commercial expansion while preserving near-term liquidity. In the context of biotech finance, such arrangements can alter the earnings narrative by shifting some future revenue volatility into a defined royalty stream, which matters for EPS considerations and EPS consensus among equity analysts. The flexibility could help management prioritize R&D and pivotal trials without forcing a near-term accelerant in selling, general, and administrative activity purely to hit an implied earnings target.

What this could portend for ADCT and peers

ADCT’s 2025 results underscore a company in transition: revenue is growing from a narrow base, cash burn remains a reality, and the real equity story hinges on successful LOTIS data readouts and the regulatory path ahead. For ADCT investors, the narrative now folds into a classic biotech hinge: can LOTIS deliver durable clinical benefits that translate into an approved, commercial product and a sustainable revenue stream? The answer will be watched alongside peers pursuing ADC platforms or hematologic-oncology franchises with similar dependency on late-stage trial outcomes and regulatory milestones.

From a sector perspective, the emphasis on partnerships, strategic financing, and a robust data cadence is a recurring theme. The reliance on a few pivotal data releases—LOTIS-5 topline in 2026, LOTIS-5/LOTIS-7 full data by year-end 2026—means the stock may exhibit pronounced sensitivity to Phase 3 narratives and FDA feedback, rather than steady-state quarterly operating metrics. In other words, the earnings landscape for ADCT and its ADC-sector peers remains highly data-driven, with big value creation riding on a handful of data disclosures and regulatory decisions rather than incremental quarterly revenue deltas.

Bottom line

ADCT delivered a financially cautious, data-forward update: modest Q4 revenue gains, disciplined cost management, and a clear line of sight to several high-impact catalysts. The company’s TAM in ZYNLONTA and related regimens will, in the near term, hinge on LOTIS-5 and LOTIS-7 outcomes and FDA/regulatory navigation, all under a financing framework designed to cushion the burn while trials mature. For investors tracking EPS and revenue forecast across the space, ADCT is a reminder that in biotech, the earnings surprise will be less about immediate profit and more about whether a handful of trials can convert into a durable commercial franchise.